Eli Lilly's Foundayo Gains Rapid Market Share in Oral Weight-Loss Segment
Eli Lilly’s newly launched oral obesity drug, Foundayo, has captured over 30% of new U.S. patients starting oral weight-loss treatments within months of its April 2026 launch. This rapid market share gain is significant as it challenges Novo Nordisk's Wegovy pill, which previously held about 90% of the oral obesity drug segment. The broader U.S. obesity-drug market is projected to exceed $100 billion annually by 2030, with oral treatments expected to account for more than one-third of GLP-1 use. Foundayo offers a practical advantage as it can be taken at any time without food or water restrictions and has shown an average weight reduction of 12.4% in clinical trials. The drug is priced between $25–$149 per month, depending on insurance coverage, making it accessible to various patient groups. Lilly's existing GLP-1 drugs already account for 65% of its revenue in the first half of 2026, and Foundayo could further expand this cardiometabolic portfolio. However, early success does not guarantee long-term adherence or sustained market share. Novo Nordisk is developing lower-dose versions of Wegovy to improve affordability and flexibility, which may intensify competition.
Topics: Eli Lilly Foundayo GLP-1 oral medications market share Wegovy